Bli medlem
Bli medlem

Du är här


Vitrolife AB (publ): Annual Report 2013

Today Vitrolife is publishing the Annual Report for 2013 in Swedish.
The Annual Report is attached to this press release and will also be
available on

The printed version of the Annual Report will be distributed by mail
during the week commencing 22 April. It will be distributed to Nordic
shareholders who are new from last year and to remaining shareholders
who have requested that the annual report should be sent to them.

The printed version of the Annual Report can be ordered on the
company's website
(, by phone +46 (0)31 721 80
00 or by email

Gothenburg, Sweden

April 11, 2014


Queries should be addressed to:

Mikael Engblom, CFO, tel 46 31 721 80 14

Vitrolife is required to publish the information in this press release
in accordance with the Swedish Securities Market Act and/or the
Financial Instruments Trading Act. The information was submitted for
publication on April 11, 2014 at 08:30 a.m.

This is a translation of the Swedish version of the press release.
When in doubt, the Swedish wording prevails.


Vitrolife ( is an international
medical device Group. Vitrolife Fertility
( product area develops,
produces and markets medical devices for assisted reproduction. Work
is also carried out to enable the use and handling of stem cells for
therapeutic purposes

Vitrolife ( has approximately
240 employees and the company's products are sold in almost 110
markets. The company is headquartered in Gothenburg, Sweden, and
there are also offices in USA, Australia, France, Italy, United
Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share
( is
listed on NASDAQ OMX Stockholm
Small Cap.


Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate
identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80
99. E-mail: Website:


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.